Q&A

After a decade of working with the Phelan-McDermid Syndrome Foundation, Geraldine Bliss has co-founded a new organization to develop therapies for the condition.

Khara Ramos explains how the Brain Initiative incorporates the emerging field of ‘neuroethics’ into the research it funds.

Molecular biologist Jonathan Mill is probing gene expression’s role in autism in uncharted territory — the fetal human brain.

Researcher Randi Hagerman is a big proponent of metformin — a diabetes drug that she is testing in people with fragile X syndrome. In fact, Hagerman takes the drug herself as a preventive measure against cancer.

Annie Ciernia describes the greenhouse origins of her scientific career and why a unicorn makes a good lab mascot.

Mikle South spends his days teaching classes, studying the relationship between anxiety and autism, and coping with living in a conservative state.

Clinical psychologist Adam Guastella is driven to develop treatments that work for all autistic people — and to throw birthday parties for a few of those people.

Lilia Iakoucheva spends her days running outdoors and solving the molecular complexities of autism, sometimes at the same time.

Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.

Gabriela Rosenblau relives the joys — and pains — of setting up a new lab.